"""
COMPREHENSIVE DRUG DESIGN & DEVELOPMENT PLATFORM
From Target Selection to Clinical Phases

For GM sir - Complete Drug Discovery Pipeline
"""

# ==========================================
# MODULE 1: TARGET SELECTION & VALIDATION
# ==========================================

TARGET_DATABASES = {
    "UniProt": "https://www.uniprot.org",
    "PDB": "https://www.rcsb.org",
    "AlphaFold": "https://alphafold.ebi.ac.uk",
    "KEGG": "https://www.genome.jp/kegg",
    "Reactome": "https://reactome.org",
    "DisGeNET": "https://www.disgenet.org",
    "CTD": "https://ctdbase.org",
    "OpenTargets": "https://platform.opentargets.org",
}

PROTEIN_CLASSES = {
    "Enzyme": ["Kinase", "Protease", "Phosphatase", "Hydrolase", "Transferase", "Oxidoreductase", "Isomerase", "Ligase", "Lyase"],
    "Receptor": ["GPCR", "RTK", "Nuclear receptor", "Ion channel", "Transporter"],
    "Transcription Factor": ["Zinc finger", "Helix-turn-helix", "Basic leucine zipper"],
    "Structural Protein": ["Membrane protein", "Cytoskeletal", "ECM"],
    "Immune": ["Cytokine", "Complement", "Antibody target"],
}

DISEASE_PATHWAYS = {
    "Cancer": ["RTK signaling", "PI3K/AKT", "MAPK", "Cell cycle", "Apoptosis", "DNA repair", "Angiogenesis", "Immune checkpoint"],
    "Diabetes": ["Insulin signaling", "GLP-1 pathway", "PPAR pathway", "Gluconeogenesis", "Lipid metabolism"],
    "Cardiovascular": ["RAAS", "Beta adrenergic", "Calcium signaling", "Coagulation cascade"],
    "Neurological": ["Dopaminergic", "Serotonergic", "GABAergic", "Glutamatergic", "Cholinergic", "Opioid system"],
    "Inflammatory": ["TNF-alpha pathway", "IL-6 pathway", "JAK/STAT", "NF-kB pathway", "COX/PGE2"],
    "Antimicrobial": ["Cell wall synthesis", "Protein synthesis", "DNA replication", "Folate synthesis", "Topoisomerase"],
}

TARGET_VALIDATION_METHODS = [
    "RNAi/siRNA knockdown",
    "CRISPR/Cas9 knockout",
    "CRISPRi/a activation",
    "Overexpression studies",
    "Transgenic models",
    "Patient-derived cells",
    "Organoid models",
    "Phenotypic screening",
]

# ==========================================
# MODULE 2: HIT IDENTIFICATION
# ==========================================

VIRTUAL_SCREENING_METHODS = {
    "Structure-based": [
        "High-throughput VS (HTVS)",
        "Standard VS (SVS)",
        "Extra precision (XP) docking",
        "Induced fit docking (IFD)",
        "Glide docking with constraints",
        "MM-GBSA binding free energy",
        "QM/MM calculations",
    ],
    "Ligand-based": [
        "Similarity search",
        "Pharmacophore matching",
        "Shape-based screening",
        "Machine learning models",
        "Deep learning (CNN, GNN)",
        "Molecular fingerprints",
        "Descriptor-based QSAR",
    ],
    "Fragment-based": [
        "NMR fragment screening",
        "X-ray fragment screening",
        "DELF fragment screening",
        "TLC fragment binding",
        "SPR fragment screening",
    ],
}

NATURAL_PRODUCT_SOURCES = [
    "Marine sponges (Pseudoceratina, Stylissa)",
    "Coral (Sarcophyton, Sinularia)",
    "Sea slug (Dolabella auricularia)",
    "Plant alkaloids (Papaver, Ephedra, Atropa)",
    "Fungal metabolites (Penicillium, Aspergillus)",
    "Bacterial metabolites (Streptomyces)",
    "Marine bacteria (Salinispora)",
    "Cyanobacteria (Lyngbya, Moorea)",
]

HTS_ANALYSIS = {
    "Primary screening": "Hit rate calculation, Z-factor, S/B ratio",
    "Counter screening": "Pan-assay interference compounds (PAINS)",
    "Dose-response": "IC50, EC50, hill slope determination",
    "Hit confirmation": "qHTS, orthogonal assays",
}

# ==========================================
# MODULE 3: LEAD OPTIMIZATION
# ==========================================

SAR_ANALYSIS_TOOLS = [
    "Free-Wilson analysis",
    "Receptor-based SAR",
    "Matched molecular pairs (MMP)",
    "Linear free energy relationships (LFER)",
    "3D-QSAR (CoMFA, CoMSIA)",
    "ML-based QSAR/QSPR",
    "GNN-based property prediction",
]

BIOISOSTERE_REPLACEMENTS = {
    "Ring bioisosteres": [
        ("Benzene", "Pyridine, Thiophene, Furan, Pyrrole, Cyclohexane"),
        ("Phenyl", "Pyridyl, Thienyl, Furyl, Indole, Naphthyl"),
        ("Imidazole", "Triazole, Tetrazole, Oxazole, Thiazole"),
        ("Purine", "Pyridopyrimidine, Pyrrolopyrimidine"),
    ],
    "Functional group bioisosteres": [
        ("COOH", "SO2NH2, PO(OH)2, Tetrazole, Hydroxamic acid"),
        ("OH", "NH2, SH, CH2OH, F"),
        ("COOR", "COSR, SO2R, PO(OR)2"),
        ("CONH2", "SO2NH2, PO(NH2)2"),
        ("Cl", "F, Br, CF3, OCF3, SCF3"),
        ("CH3", "Et, iPr, tBu, cyclopropyl"),
    ],
    "Permutation bioisosteres": [
        ("Primary amine", "Secondary amine, Diazine, Morpholine"),
        ("Ester", "Amide, Ketone, Sulfonamide"),
        ("Carboxylic acid", "Tetrazole, Hydroxamic acid, Phosphonic acid"),
    ],
}

ADMET_PROPERTIES = {
    "Absorption": [
        "Caco-2 permeability",
        "MDCK permeability",
        "Human intestinal absorption (HIA)",
        "Pgp substrate/inhibitor",
        "BCS classification",
    ],
    "Distribution": [
        "Plasma protein binding",
        "Blood-brain barrier (BBB) penetration",
        "Volume of distribution (VD)",
        "Tissue distribution",
    ],
    "Metabolism": [
        "CYP450 inhibition (1A2, 2C9, 2C19, 2D6, 3A4)",
        "CYP450 induction",
        "Half-life (t1/2)",
        "Clearance (CL)",
        "FMO oxidation",
    ],
    "Excretion": [
        "Renal excretion",
        "Hepatic clearance",
        "Biliary excretion",
    ],
    "Toxicity": [
        "hERG inhibition (cardiotoxicity)",
        "Ames test (mutagenicity)",
        "Hepatotoxicity (DILI)",
        "Pulmonary toxicity",
        "Developmental toxicity",
        "Safety pharmacology panels",
    ],
}

PROPERTY_TARGETS = {
    "Lipinski's Rule of 5": {
        "MW": "< 500 Da",
        "LogP": "< 5",
        "HBD": "<= 5",
        "HBA": "<= 10",
    },
    "Beyond Rule of 5": {
        "P-gp substrate": "For brain penetration",
        "High solubility": "> 100 μg/mL",
        "High permeability": "> 5x10^-6 cm/s",
    },
    "CNS drug-like": {
        "MW": "< 400 Da",
        "LogP": "1-4",
        "TPSA": "< 90 A2",
        "Rotatable bonds": "< 8",
        "PPB": "< 95%",
    },
}

# ==========================================
# MODULE 4: PRECLINICAL DEVELOPMENT
# ==========================================

IN_VITRO_ASSAYS = {
    "Binding assays": ["Radioligand binding", "FP binding", "SPA binding", "TR-FRET"],
    "Functional assays": ["GTPgammaS", "cAMP accumulation", "Calcium flux", "Reporter gene", "PathHunter"],
    "Enzyme assays": ["Continuous", "Stop reagent", "ADP detection", "Substrate depletion"],
    "Cell-based": ["Reporter assay", "Cell viability", "Flow cytometry", "Imaging", "Electrophysiology"],
}

IN_VIVO_MODELS = {
    "Oncology": ["Xenograft", "Syngeneic", "PDX", "GEMM", "Orthotopic"],
    "Metabolic": ["db/db mouse", "ob/ob mouse", "ZDF rat", "DIO mouse"],
    "Cardiovascular": ["DOCA-salt rat", "SHR rat", "L-NAME rat", "MI mouse"],
    "Neurological": ["MPTP mouse", "6-OHDA rat", "Rotenone rat", "APP/PS1 mouse", "SOD1 mouse"],
    "Inflammatory": ["CIA mouse", "MOG-EAE", "TNBS mouse", "LPS mouse", "OVA rat"],
    "Antimicrobial": ["Murine sepsis", "Pneumonia", "UTI", "Cellulitis", "Thigh infection"],
}

TOXICOLOGY_PREDICTION = {
    "Computational": [
        "Derek Nexus (liver toxicity)",
        "Sarah Nexus (genotoxicity)",
        "MC4LP (developmental toxicity)",
        "Timgenesis (carcinogenicity)",
        "TOPKAT (skin sensitization)",
        "LAZAR (organ toxicity)",
    ],
    "Organ toxicity panels": [
        "Cardiovascular (hERG, action potential)",
        "Hepatic (ALT, AST, LDH)",
        "Renal (creatinine, BUN)",
        "Hematological (CBC)",
        "Pulmonary (lung function)",
    ],
    "Genotoxicity": [
        "Ames test",
        "In vitro micronucleus",
        "Comet assay",
        "Chromosome aberration",
    ],
}

PKPD_MODELING = {
    "PK parameters": ["AUC", "Cmax", "Tmax", "t1/2", "CL", "VD", "F%", "PPB"],
    "PD markers": ["Biomarker levels", "Receptor occupancy", "Pharmacodynamic effect"],
    "Allometric scaling": ["Monkey-Human", "Dog-Human", "Rat-Human"],
    "IVIVC": ["Correlation development", "waiver"],
}

# ==========================================
# MODULE 5: CLINICAL DEVELOPMENT
# ==========================================

CLINICAL_PHASES = {
    "Phase I": {
        "Purpose": "Safety, tolerability, PK/PD",
        "Population": "Healthy volunteers (20-100)",
        "Endpoints": ["Dose escalation MTD", "Safety biomarkers", "Initial efficacy signals"],
        "Duration": "6-12 months",
    },
    "Phase II": {
        "Purpose": "Efficacy, dose-finding",
        "Population": "Patients (100-500)",
        "Endpoints": ["Clinical response", "Biomarker modulation", "Optimal dose"],
        "Duration": "12-24 months",
    },
    "Phase III": {
        "Purpose": "Confirm efficacy, safety",
        "Population": "Patients (1000-5000)",
        "Endpoints": ["Clinical outcome", "Adverse events", "Quality of life"],
        "Duration": "24-48 months",
    },
    "Phase IV": {
        "Purpose": "Post-marketing surveillance",
        "Population": "All patients",
        "Endpoints": ["Long-term safety", "Rare adverse events", "New indications"],
        "Duration": "Ongoing",
    },
}

TRIAL_DESIGNS = [
    "Parallel group",
    "Crossover",
    "Factorial",
    "Adaptive (group sequential)",
    "Seamless Phase II/III",
    "Basket trial",
    "Umbrella trial",
    "Platform trial",
]

ENDPOINT_TYPES = {
    "Clinical": ["Overall survival (OS)", "Progression-free survival (PFS)", "Disease-free survival (DFS)", "Event-free survival (EFS)"],
    "Surrogate": ["Objective response rate (ORR)", "Complete response (CR)", "Partial response (PR)", "Stable disease (SD)"],
    "Patient-reported": ["QoL scores", "Symptom scales", "Functional scales"],
    "Biomarker": ["Imaging response", "Biochemical markers", "Pathological response"],
}

# ==========================================
# MODULE 6: COMPUTATIONAL TOOLS
# ==========================================

MOLECULAR_DOCKING = {
    "Autodock Vina": {"speed": "Fast", "accuracy": "Medium", "gpu": False},
    "Glide": {"speed": "Medium", "accuracy": "High", "gpu": False},
    "Gold": {"speed": "Medium", "accuracy": "High", "gpu": False},
    "PLANTS": {"speed": "Fast", "accuracy": "High", "gpu": False},
    "Dock6": {"speed": "Slow", "accuracy": "Medium", "gpu": False},
    "CUDAdock": {"speed": "Very fast", "accuracy": "High", "gpu": True},
}

MOLECULAR_DYNAMICS = {
    "GROMACS": {"type": "Classical MD", "speed": "Fast", "scale": "Millions of atoms"},
    "AMBER": {"type": "Classical MD", "speed": "Medium", "scale": "Hundreds of thousands"},
    "NAMD": {"type": "Classical MD", "speed": "Fast", "scale": "Millions of atoms"},
    "OpenMM": {"type": "Classical MD", "speed": "Medium", "gpu": True},
    "Desmond": {"type": "Classical MD", "speed": "Fast", "gpu": True},
    "CHARMM": {"type": "QM/MM", "speed": "Slow", "accuracy": "Very high"},
}

QSAR_TOOLS = [
    "MOE",
    "Discovery Studio",
    "Schrodinger Canvas",
    "KNIME",
    "RDKit",
    "PyMOL",
    "Chimera",
]

MACHINE_LEARNING = {
    "Supervised Learning": ["Random Forest", "SVM", "Gradient Boosting", "Neural Networks", "GNN"],
    "Unsupervised Learning": ["K-means", "PCA", "t-SNE", "UMAP"],
    "Deep Learning": ["CNN", "RNN/LSTM", "Transformer", "Graph Neural Network", "Attention"],
    "Active Learning": ["Bayesian optimization", "Gaussian processes"],
}

ALPHAFOLD_FEATURES = [
    "Sequence alignment (MSA)",
    "Template modeling",
    "Model confidence (pLDDT)",
    "Disorder prediction",
    "Domain prediction",
    "Interface prediction",
]

# ==========================================
# MODULE 7: DATABASE REFERENCES
# ==========================================

DRUG_DATABASES = {
    "ChEMBL": "https://www.ebi.ac.uk/chembl",
    "PubChem": "https://pubchem.ncbi.nlm.nih.gov",
    "DrugBank": "https://www.drugbank.ca",
    "BindingDB": "https://www.bindingdb.org",
    "PDSP Ki database": "https://pdsp.unc.edu",
    "Guide to Pharmacology": "https://www.guidetopharmacology.org",
}

PROTEIN_DATABASES = {
    "UniProt": "https://www.uniprot.org",
    "PDB": "https://www.rcsb.org",
    "AlphaFold DB": "https://alphafold.ebi.ac.uk",
    "STRING": "https://string-db.org",
    "BioGRID": "https://thebiogrid.org",
    "IntAct": "https://www.ebi.ac.uk/intact",
}

CHEMINFORMATICS_TOOLS = {
    "RDKit": "Molecular fingerprints, descriptors, SAR analysis",
    "Open Babel": "Format conversion, SMILES manipulation",
    "PyMOL": "Molecular visualization",
    "Chimera": "Molecular visualization, analysis",
    "ChemDraw": "Structure drawing, naming",
    "Schrodinger": "Docking, MD, QSAR, LiFE",
    "MOE": "QSAR, pharmacophore, docking",
    "Knime": "Workflow automation",
}

# ==========================================
# COMPLETE DRUG PIPELINE STEPS
# ==========================================

DRUG_DISCOVERY_PIPELINE = [
    {
        "Stage": 1,
        "Name": "Target Identification",
        "Duration": "3-6 months",
        "Tools": ["Genomics", "Proteomics", "Bioinformatics", "Literature mining"],
        "Databases": ["UniProt", "PDB", "AlphaFold", "OpenTargets"],
        "Deliverables": ["Target list", "Disease association", "Genetic validation"],
    },
    {
        "Stage": 2,
        "Name": "Target Validation",
        "Duration": "6-12 months",
        "Tools": ["RNAi", "CRISPR", "siRNA", "Overexpression"],
        "Databases": ["CRISPR screening", "RNAi databases", "GTEx"],
        "Deliverables": ["Validated target", "Assay development", "BioMarkers"],
    },
    {
        "Stage": 3,
        "Name": "Hit Identification",
        "Duration": "12-24 months",
        "Tools": ["VS", "HTS", "Fragment screening", "Natural products"],
        "Databases": ["ChEMBL", "PubChem", "ZINC", "Maybridge"],
        "Deliverables": ["Hit series", "Hit confirmation", "Primary SAR"],
    },
    {
        "Stage": 4,
        "Name": "Lead Optimization",
        "Duration": "24-36 months",
        "Tools": ["SAR", "ADMET prediction", "Bioisosteres", "Retrosynthesis"],
        "Databases": ["ADMET", "eDrugPortal", "HSDB"],
        "Deliverables": ["Optimized lead", "In vitro efficacy", "In vivo PK/PD"],
    },
    {
        "Stage": 5,
        "Name": "Preclinical Development",
        "Duration": "12-24 months",
        "Tools": ["In vitro assays", "In vivo models", "Safety assessment"],
        "Databases": ["ToxNet", "DrugMatrix"],
        "Deliverables": ["IND-enabling studies", "Toxicology package", "CMC"],
    },
    {
        "Stage": 6,
        "Name": "Phase I Clinical Trials",
        "Duration": "6-12 months",
        "Tools": ["Human PK/PD", "Safety monitoring"],
        "Databases": ["ClinicalTrials.gov", "FDA Orange Book"],
        "Deliverables": ["Safety data", "Dose selection", "Initial efficacy"],
    },
    {
        "Stage": 7,
        "Name": "Phase II Clinical Trials",
        "Duration": "12-24 months",
        "Tools": ["Proof of concept", "Dose-response"],
        "Databases": ["ClinicalTrials.gov"],
        "Deliverables": ["Efficacy data", "Biomarker validation"],
    },
    {
        "Stage": 8,
        "Name": "Phase III Clinical Trials",
        "Duration": "24-48 months",
        "Tools": ["Pivotal efficacy", "Large-scale safety"],
        "Databases": ["ClinicalTrials.gov", "Regulatory submissions"],
        "Deliverables": ["Confirmatory efficacy", "NDA/BLA filing"],
    },
    {
        "Stage": 9,
        "Name": "Approval & Launch",
        "Duration": "12-18 months",
        "Tools": ["Regulatory review", "Manufacturing scale-up"],
        "Databases": ["FDA", "EMA", "PMDA"],
        "Deliverables": ["Regulatory approval", "Market launch"],
    },
    {
        "Stage": 10,
        "Name": "Phase IV / Post-marketing",
        "Duration": "Ongoing",
        "Tools": ["PV surveillance", "Real-world evidence"],
        "Databases": ["FAERS", "VigiBase"],
        "Deliverables": ["Safety monitoring", "New indications"],
    },
]

print("""
============================================================
    COMPREHENSIVE DRUG DESIGN & DEVELOPMENT PLATFORM
                    From Target to Clinic
============================================================

  STAGES COVERED:
  1. Target Identification & Validation
  2. Hit Identification (Virtual/Physical Screening)
  3. Lead Optimization (SAR, ADMET, Retrosynthesis)
  4. Preclinical Development (In vitro/In vivo)
  5. Clinical Development (Phase I-IV)
  6. Regulatory Approval
  7. Post-marketing Surveillance

  TOOLS INCLUDED:
  - Molecular docking (AutoDock, Glide, GOLD)
  - Molecular dynamics (GROMACS, AMBER, NAMD)
  - ML/AI for QSAR and drug design
  - Bioisostere replacements
  - Retrosynthesis (IBM RXN, ASKCos)
  - ADMET prediction

  DATABASE LINKS:
  - ChEMBL, PubChem, DrugBank, BindingDB
  - UniProt, PDB, AlphaFold
  - ClinicalTrials.gov

============================================================
""")

# Export for use in other modules
__all__ = [
    "TARGET_DATABASES",
    "PROTEIN_CLASSES",
    "DISEASE_PATHWAYS",
    "TARGET_VALIDATION_METHODS",
    "VIRTUAL_SCREENING_METHODS",
    "NATURAL_PRODUCT_SOURCES",
    "HTS_ANALYSIS",
    "SAR_ANALYSIS_TOOLS",
    "BIOISOSTERE_REPLACEMENTS",
    "ADMET_PROPERTIES",
    "PROPERTY_TARGETS",
    "IN_VITRO_ASSAYS",
    "IN_VIVO_MODELS",
    "TOXICOLOGY_PREDICTION",
    "PKPD_MODELING",
    "CLINICAL_PHASES",
    "TRIAL_DESIGNS",
    "ENDPOINT_TYPES",
    "MOLECULAR_DOCKING",
    "MOLECULAR_DYNAMICS",
    "QSAR_TOOLS",
    "MACHINE_LEARNING",
    "ALPHAFOLD_FEATURES",
    "DRUG_DATABASES",
    "PROTEIN_DATABASES",
    "CHEMINFORMATICS_TOOLS",
    "DRUG_DISCOVERY_PIPELINE",
]